Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Mid Cap
Health Score : 8.08Alkem Laboratories demonstrates a strong financial position, particularly in solvency, growth, and profitability. The company maintains a healthy balance sheet with low debt levels and robust equity. Revenue and earnings growth are impressive, indicating effective management and market positioning. Profitability metrics, such as ROCE, ROE, and ROA, consistently reflect efficient capital utilization. However, there are some areas of concern, notably in efficiency and liquidity. The company's turnover ratios for fixed assets, inventory, and capital are low, suggesting potential inefficiencies in asset utilization. While the company exhibits high liquidity, its cash flow management needs improvement. Capital expenditure is a key area needing attention, as it impacts overall financial health. Despite these challenges, Alkem's strong performance in core areas positions it well for future growth and stability within the healthcare industry.
Health Score : 8.08Alkem Laboratories demonstrates a strong financial position, particularly in solvency, growth, and profitability. The company maintains a healthy balance sheet with low debt levels and robust equity. Revenue and earnings growth are impressive, indicating effective management and market positioning. Profitability metrics, such as ROCE, ROE, and ROA, consistently reflect efficient capital utilization. However, there are some areas of concern, notably in efficiency and liquidity. The company's turnover ratios for fixed assets, inventory, and capital are low, suggesting potential inefficiencies in asset utilization. While the company exhibits high liquidity, its cash flow management needs improvement. Capital expenditure is a key area needing attention, as it impacts overall financial health. Despite these challenges, Alkem's strong performance in core areas positions it well for future growth and stability within the healthcare industry.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
29.00
Industry Median
30.91
Mid Cap Median
44.19
P/E RATIO
27.53
P/B RATIO
4.58
Industry Median
3.69
Mid Cap Median
6.64
P/S RATIO
4.35
Industry Median
3.74
Mid Cap Median
6.84
Others
PEG RATIO
3.55
EV/EBITDA RATIO
18.51
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹5300 as on Sep 1, 2026.
Growth Score : 10.00Alkem Laboratories demonstrates outstanding growth across all key metrics. Revenue, operating profit, EPS, assets, and net income are all growing at high rates. This reflects strong market positioning, effective management strategies, and a robust ability to capitalize on opportunities. The company's consistent growth underscores its financial health and potential for future success.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 19.95 | 9.07 | 9.22 | 2.34 | 13.47 |
| Operating Profit Growth Rate | 5.6 | -21.03 | 38.66 | 11.69 | 19.63 |
| Earnings Per Share (EPS) Growth | 3.82 | -40.19 | 82.47 | 20.59 | 6.29 |
| Asset Growth Rate | 22.14 | -2.22 | 13.22 | 13.59 | 17.99 |
| Net Income Growth Rate | 3.83 | -40.06 | 79.84 | 22.31 | 6.14 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Abbott India Ltd | 8.68 | 35.78 | Neutral | 1892.00 | 730.39 | 1552.00 |
| 2 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 49.00 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 3 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 4 | Alkem Laboratories Ltd | 8.08 | 27.53 | Neutral | 3005.00 | 182.76 | 2351.00 |
| 5 | Gland Pharma Ltd | 7.91 | 46.11 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 6 | Lupin Ltd | 7.84 | 18.46 | Neutral | 8816.00 | 139.24 | 5355.00 |
| 7 | Ajanta Pharma Ltd | 7.72 | 41.47 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 8 | Mankind Pharma Ltd | 7.61 | 50.85 | Overvalued | 3617.00 | 49.34 | 1938.00 |
| 9 | Zydus Lifesciences Ltd | 7.60 | 23.31 | Neutral | 8475.00 | 35.69 | 5124.00 |
| 10 | Laurus Labs Ltd | 7.10 | 113.10 | Neutral | 1778.00 | 13.71 | 890.00 |
| 11 | Dr Reddys Laboratories Ltd | 6.68 | 23.29 | Neutral | 6454.00 | 38.57 | 4158.00 |
| 12 | Glenmark Pharmaceuticals Ltd | 6.36 | 51.19 | Neutral | 4572.00 | -7.12 | 1362.00 |
| 13 | Ipca Laboratories Ltd | 6.33 | 44.19 | Overvalued | 1979.00 | 44.64 | 1184.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Alkem Laboratories Ltd. is a leading Indian pharmaceutical company primarily engaged in developing, manufacturing, and marketing branded generics, active pharmaceutical ingredients (APIs), and nutraceuticals. It holds a strong market position in India across various therapeutic areas, complemented by a growing international presence, particularly in the US generics market.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Alkem Laboratories Ltd's P/E ratio (TTM) is 29.00, compared to the industry median of 30.91 and large cap median of 44.19.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Alkem Laboratories Ltd's P/B ratio is 4.58, compared to the industry median of 3.69 and large cap median of 6.64.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Alkem Laboratories Ltd's P/S ratio is 4.35, compared to the industry median of 3.74 and large cap median of 6.84.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Alkem Laboratories Ltd's PEG ratio is 3.55.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Alkem Laboratories Ltd's EV/EBITDA ratio is 18.51.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Alkem Laboratories Ltd's ROE is 17.01%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Alkem Laboratories Ltd's ROA is 14.40%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Alkem Laboratories Ltd's ROCE is 21%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Alkem Laboratories Ltd's operating margin is 20.43%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Alkem Laboratories Ltd's net margin is 15.98%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Alkem Laboratories Ltd's current ratio is 2.42.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Alkem Laboratories Ltd's debt-to-equity ratio is 0.06.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Alkem Laboratories Ltd's interest coverage ratio is 18.83.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Alkem Laboratories Ltd's DPS is ₹53.90.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Alkem Laboratories Ltd's EPS is 6.29.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹5300. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1973
Headquarters: Mumbai, Maharashtra
Core Offerings: Branded generics, Active Pharmaceutical Ingredients (APIs), Nutraceuticals, Over-the-Counter (OTC) products
Stock Listing: NSE (ALKEM), BSE (539523)
Promoter: Singh Family / Basudeo N. Singh
1973: Incorporated by Mr. Samprada Singh. 1978: Launched its iconic anti-infective brand 'Taxim', which became a market leader. 1989: Commenced international operations with initial exports. 2000s: Significantly expanded manufacturing footprint, including establishing USFDA-approved facilities. 2016: Successfully completed its Initial Public Offering (IPO) and listed on NSE and BSE. Present: Continues to be a significant player in the Indian and global pharmaceutical markets, with a diverse therapeutic portfolio.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| India Business | 68% (FY23) | Higher EBITDA margins due to branded generics focus |
| International Business | 32% (FY23) | Margins influenced by regulatory and competitive landscape |
India Business: Focuses on branded generics across key therapy areas such as anti-infectives, gastrointestinal, pain management, and vitamins. Supported by a robust distribution network and a large medical representative force.
International Business: Primarily driven by generics in the US market (ANDA filings) and a growing presence in emerging markets. This segment includes both finished dosage forms and some Active Pharmaceutical Ingredients (APIs).
Basudeo N. Singh (Executive Chairman): A visionary leader and co-founder, he has been instrumental in Alkem's journey, guiding its strategic direction and growth for over five decades. Sandeep Singh (Managing Director): With extensive experience in the pharmaceutical sector, he leads the company's day-to-day operations and drives its growth initiatives, focusing on market expansion and operational excellence.
Enzene Biosciences Limited (focuses on biologics and biosimilars)
Alkem Laboratories (America) Inc. (handles US market operations)
Cachet Pharmaceuticals Private Limited (acquired company, reinforces India presence)
Pharmacare Ltd (Mauritius)
2016: Initial Public Offering (IPO) on NSE and BSE. 2017: Acquisition of Cachet Pharmaceuticals Private Limited, strengthening its domestic market presence. No major recent corporate actions on record.
The Alkem Laboratories Ltd share price today is ₹5300 on NSE (ALKEM), as of 25 Sept 2026.
As of 25 Sept 2026, Alkem Laboratories Ltd share price is ₹5300, with previous close ₹5300. Today's range is ₹5300 to ₹5300. The 52-week range is ₹5051 to ₹5933.50.
As of today, Alkem Laboratories Ltd's market cap is ₹64,024 crore (Large Cap).
Alkem Laboratories Ltd's current P/E ratio is 29.00, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 33.
Alkem Laboratories Ltd's current P/B ratio is 4.58.
Alkem Laboratories Ltd's current dividend yield is 1.02%. Last dividend of ₹15.00 per share was declared on 07-Mar-2024.
Alkem Laboratories Ltd's EPS (TTM) is ₹6.29.
Alkem Laboratories Ltd. is a leading Indian pharmaceutical company primarily engaged in developing, manufacturing, and marketing branded generics, active pharmaceutical ingredients (APIs), and nutraceuticals. It holds a strong market position in India across various therapeutic areas, complemented by a growing international presence, particularly in the US generics market.
Alkem Laboratories Ltd is promoted by Singh Family / Basudeo N. Singh, holding 51.2% as of 25 Sept 2026.
Alkem Laboratories Ltd is listed on NSE (ALKEM) and BSE (539523). Its next quarterly results are expected on August 2024 (Q1 FY25).
Capital Expenditures (CapEx)
